The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.

Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. | Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today presented positive results from the DELTA 1 trial in one of two LEO Pharma late-breaking sessions at ...

LEO Pharma is expanding upon its ambitions in the United States (U.S.) as the FDA has accepted for filing the company’s New Drug Application (NDA) for delgocitinib cream, an investigational innovative ...

Watch out, Incyte: Leo Pharma’s topical JAK inhibitor is catching up. In a late-stage trial in moderate to severe chronic hand eczema, Leo Pharma's delgocitinib cream met its primary and secondary ...

Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that blocks the activation of the JAK-STAT pathway. The Food and Drug Administration (FDA) has granted Fast Track designation to delgocitinib ...

LEO Pharma A/S, a global leader in medical dermatology, has today announced submission of the New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for Anzupgo® ...

Leo's Homemade Ice Cream in South Middleton Twp. is one of the 10 top ice cream shops in the nation, according to TripAdvisor. JOHN C. WHITEHEAD/The Patriot-News Just in time for the July Fourth, ...

The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in ...

LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN ...